TDM-105795

The evidence base is a patent, a regulatory filing, a substance registry and three registered trials. There are zero peer-reviewed publications of this compound's data.

The phase 2a has posted registry results. ⚠️ Four problems are visible in them. They carry no statistics of any kind. The primary endpoint figure disagrees with the number in the company's own press release, 22.4 against 24.3. The differences between treatment arms are smaller than the standard deviations within those arms. And hair width, a secondary measure, trended against the drug. The results were posted about 21 months after the press release announcing them.

⚠️ The concept was not novel when it was filed. A 2010 Pfizer paper reported a beta-selective thyromimetic effective in both mouse and monkey hair-growth models after topical application, with serum levels below the limit of quantification in bald macaques ^[1]. That is four years before this compound's priority date, includes a primate model this programme has never published, and describes exactly the differentiating profile now claimed for it. Two further patent families from the same era also claim thyromimetics for hair loss. ⚠️ The prior-art point stands on the concept rather than the molecule: the Pfizer compound appears to be a different chemotype.

There has been no public activity on this compound since February 2024. No phase 3 exists, no ex-Asia partner has been announced, and no discontinuation notice has been issued either, so absence of news is not evidence of termination.

⚠️ No safety data for this compound has been published in any peer-reviewed form. What exists is a phase 1 and a phase 2a trial, of which only the phase 2a has posted registry results, and those carry no safety statistics.

The animal work in the patent measured body weight as its only systemic readout. Thyroid hormone, thyroid stimulating hormone, free T4 and T3, and heart rate were not measured at all, which matters because those are precisely the endpoints a topical thyromimetic must clear. The entire premise of the compound is that it acts locally and does not reach the circulation, and the animal package does not test that premise.

The reassuring precedent comes from the prior art rather than from this molecule: Pfizer's topical thyromimetic showed serum drug levels below the limit of quantification in bald macaques and was rapidly metabolised, so systemic exposure was limited ^[1]. That is an encouraging result for the class and is not evidence about this compound.

⚠️ Because no selectivity data exists, the specific risk a beta-selective agonist is designed to avoid, which is alpha-receptor activation in heart and bone, cannot be assessed for this molecule at all.

Technoderma Medicines, a Singapore company, filed the priority application in 2014 covering a series of thyromimetics for hair growth, with the founder as an inventor. In 2020 it licensed the compound to Cutia Therapeutics for dermatology use in Asia, for a total of sixty million renminbi in upfront and milestone payments plus low single-digit royalties, retaining rights elsewhere; Cutia calls it CU-40101. The compound moved through phase 1 in China and a phase 2a elsewhere, and the trail goes quiet in early 2024. Its scientific record is unusual in shape: a fully resolved chemical identity confirmed by three independent primary documents, and essentially no published pharmacology or clinical data to attach to it.